Micrograph showing a lymph node invaded by ductal breast carcinoma, prolonging the tumor beyond the lymphatic gland. Credit: Nephron /…
Micrograph showing a lymph node invaded by ductal breast carcinoma, prolonging the tumor beyond the lymphatic gland. Credit: Nephron / Wikipedia
Breast cancer patients will soon have a better chance of combating the disease due to new pathological guidelines created by the University of Queensland researchers.
The guidelines allow pathologists to identify which patients have more aggressive forms of breast cancer, which means they can be properly classified and their treatment can be tailored.
9, the World Health Organization will incorporate these guidelines in the fifth edition of the iconic “Blue Book”, Breast tumor classification .
Research group Dr Amy McCart Reed said the team as developed the guidelines specifically investigated metaplastic breast carcinoma (MBC), a rare but aggressive form of breast cancer.
“For patients with MBC we found the number of different cell types in the tumors had a significant impact on survival,” says Dr. McCart Reed.
“The more varying tumor, the worse the patient’s prediction is likely.”
“Among patients with poor tumor type like MBC, there are some that will do well and some will do bad, and the new metric section helps us to categorize this.
“Previously, the WHO guidelines have described the different types of cancer cells in tumors without explaining pathologists specifically what and how to record.
” Now we can recommend pathologists to record the number of types of tumor morphologies because one more accurate forecasts can be made based on this. “
MBC accounts for less than five percent of all invasive breast cancer, but contributes significantly to breast cancer mortality because the tumors can be very aggressive.
UQ’s Center for Clinical Research Director of Molecular Pathology Professor Sunil Lakhani said research was possible on Due to the establishment of the Asapas-Pacific Metaplastic Breast Cancer Consortium (APMBCC).
“Creating the APMBCC brought together a sufficiently high cohort of these rare first-time tumor samples in Australasia, which was necessary to draw conclusions about these incredibly different tumors , says Dr. Lakhani.
“Research with the APMCC will help identify new therapeutic goals and identify the potential for re-adjusting existing cancer drugs.”
The study was jointly funded by the National Breast Cancer Foundation and Cancer Australia and involved Professor Sandra Toole from Garvan Institute of Medical Research in Sydney.
The study is published in Journal of Pathology .
Breast cancer breakthrough: Some tumors can stop their own proliferation
Amy Ellen McCart Reed et al. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic consequences, Journal of Patology (2018). DOI: 10.1002 / way.5184